Zobrazeno 1 - 10
of 1 978
pro vyhledávání: '"M. Ballantyne"'
Publikováno v:
International Journal of Qualitative Methods, Vol 18 (2019)
Background: The Two-Eyed Seeing approach has been advocated for use in research with Indigenous people as it creates a space for Western and Indigenous ways of knowing to come together using the best of both worldviews to aid understanding and solve
Externí odkaz:
https://doaj.org/article/2952da1dad2e4fd08fa511d71110a146
Autor:
Sairam Behera, Jonathan R. Belyeu, Xiao Chen, Luis F. Paulin, Ngoc Quynh H. Nguyen, Emma Newman, Medhat Mahmoud, Vipin K. Menon, Qibin Qi, Parag Joshi, Santica Marcovina, Massimiliano Rossi, Eric Roller, James Han, Vitor Onuchic, Christy L. Avery, Christie M. Ballantyne, Carlos J. Rodriguez, Robert C. Kaplan, Donna M. Muzny, Ginger A. Metcalf, Richard A. Gibbs, Bing Yu, Eric Boerwinkle, Michael A. Eberle, Fritz J. Sedlazeck
Publikováno v:
BMC Medical Genomics, Vol 17, Iss 1, Pp 1-15 (2024)
Abstract The abundance of Lp(a) protein holds significant implications for the risk of cardiovascular disease (CVD), which is directly impacted by the copy number (CN) of KIV-2, a 5.5 kbp sub-region. KIV-2 is highly polymorphic in the population and
Externí odkaz:
https://doaj.org/article/b08e11c0c6a64b4e840870232441e2bd
Autor:
Md Mesbah Uddin, Seyedmohammad Saadatagah, Abhishek Niroula, Bing Yu, Whitney E. Hornsby, Shriienidhie Ganesh, Kim Lannery, Art Schuermans, Michael C. Honigberg, Alexander G. Bick, Peter Libby, Benjamin L. Ebert, Christie M. Ballantyne, Pradeep Natarajan
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Clonal hematopoiesis of indeterminate potential (CHIP) is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CHIP is common among older adults, the underlying
Externí odkaz:
https://doaj.org/article/a84fedff581f4998bacccb1b7ef8aab7
A polygenic risk score of atrial fibrillation improves prediction of lifetime risk for heart failure
Autor:
Taryn Alkis, Xi Luo, Katherine Wall, Jennifer Brody, Traci Bartz, Patricia P. Chang, Faye L. Norby, Ron C. Hoogeveen, Alanna C. Morrison, Christie M. Ballantyne, Josef Coresh, Eric Boerwinkle, Bruce M. Psaty, Amil M. Shah, Bing Yu
Publikováno v:
ESC Heart Failure, Vol 11, Iss 2, Pp 1086-1096 (2024)
Abstract Aims Heart failure (HF) has shared genetic architecture with its risk factors: atrial fibrillation (AF), body mass index (BMI), coronary heart disease (CHD), systolic blood pressure (SBP), and type 2 diabetes (T2D). We aim to assess the asso
Externí odkaz:
https://doaj.org/article/ce72f0daf1734ab3a5fbf90a46faf51e
Autor:
Rebecca Vigen, Colby Ayers, Jarett Berry, Anand Rohatgi, Vijay Nambi, Christie M. Ballantyne, Torbjorn Omland, Christopher R. de Filippi, James de Lemos
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 13 (2024)
Background High‐sensitivity troponin I (hs‐cTnI) and T (hs‐cTnT) provide complementary information regarding cardiovascular disease risk. The explanation for their distinct risk profiles is incompletely understood. Methods and Results hs‐cTnI
Externí odkaz:
https://doaj.org/article/a9deaeb8daa74eefba531e086259a5f7
Publikováno v:
American Journal of Preventive Cardiology, Vol 18, Iss , Pp 100651- (2024)
High levels of lipoprotein(a) [Lp(a)] are causal for atherosclerotic cardiovascular disease (ASCVD). Lp(a) is the most prevalent inherited dyslipidemia and strongest genetic ASCVD risk factor. This risk persists in the presence of at target, guidelin
Externí odkaz:
https://doaj.org/article/f203ca7643784dacb00441aa780401e7
Autor:
Justin B. Echouffo‐Tcheugui, Sui Zhang, Roberta Florido, James S. Pankow, Erin D. Michos, Ronald B. Goldberg, Vijay Nambi, Gary Gerstenblith, Wendy S. Post, Roger S. Blumenthal, Christie M. Ballantyne, Josef Coresh, Elizabeth Selvin, Chiadi E. Ndumele
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 6 (2024)
Background It is unclear how metabolic syndrome (MetS) and diabetes affect Gal‐3 (galectin 3) levels and the resulting implications for heart failure (HF) risk. We assessed relationships of MetS and diabetes with Gal‐3, and their joint associatio
Externí odkaz:
https://doaj.org/article/2ae882273ed64fc8ac591dde05d50866
Autor:
Cady Smith, Jarett D. Berry, Rebecca Scherzer, James A. de Lemos, Vijay Nambi, Christie M. Ballantyne, Richard L. Kravitz, Anthony A. Killeen, Joachim H. Ix, Michael G. Shlipak, Simon B. Ascher
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 6 (2024)
Background Among individuals with hypertension and low diastolic blood pressure (DBP), the optimal BP target remains controversial due to concerns that BP lowering may reduce coronary perfusion. We determined the impact of intensive BP control among
Externí odkaz:
https://doaj.org/article/5343198ad31e4809b501ba574d28ffdf
Autor:
Asem I. Fitian, Michael C. Shieh, Olga A. Gimnich, Tatiana Belousova, Addison A. Taylor, Christie M. Ballantyne, Jean Bismuth, Dipan J. Shah, Gerd Brunner
Publikováno v:
Journal of Cardiovascular Development and Disease, Vol 11, Iss 6, p 181 (2024)
Background: Extracellular volume fraction (ECV), measured with contrast-enhanced magnetic resonance imaging (CE-MRI), has been utilized to study myocardial fibrosis, but its role in peripheral artery disease (PAD) remains unknown. We hypothesized tha
Externí odkaz:
https://doaj.org/article/6ffbb52646a943fd86fc48936759eac7
Autor:
William S. Weintraub, Deepak L. Bhatt, Zugui Zhang, Sarahfaye Dolman, William E. Boden, Adam P. Bress, Brandon K. Bellows, Catherine G. Derington, Sephy Philip, Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Jean‐Claude Tardif, Christie M. Ballantyne, Paul Kolm
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 1 (2024)
Background In 3146 REDUCE‐IT USA (Reduction of Cardiovascular Events With Icosapent Ethyl Intervention Trial USA) participants, icosapent ethyl (IPE) reduced first and total cardiovascular events by 31% and 36%, respectively, over 4.9 years of foll
Externí odkaz:
https://doaj.org/article/dc8430b3b4ce4e8a958569552e9dcca3